November 09, 2010
SCAI warns the Food and Drug Administration (FDA) that the practice of medicine should be enhanced, not impeded by the 510(k) reform initiative. Efforts to reform access to safe, effective and innovative products should not burden the doctor-patient relationship, slow access to the latest medical technologies, or limit the inclusion of meaningful scientific expertise in the 510(k) process.